Trilaciclib improves overall survival when given with gemcitabine/carboplatin (GC) in patients with metastatic triple negative breast cancer (mTNBC) in a randomized phase II trial

被引：0

作者：

O'Shaughnessy, J. ^{[1
]}

Wright, G. S. ^{[2
]}

Thummala, A. ^{[3
]}

Danso, M. ^{[4
]}

Popovic, L. S. ^{[5
]}

Pluard, T. ^{[6
]}

Han, H. S. ^{[7
]}

Vojnovic, Z. ^{[8
]}

Vasev, N. ^{[9
]}

Ma, L. ^{[10
]}

Richards, D. A. ^{[11
]}

Wilks, S. ^{[12
]}

Milenkovic, D. M. ^{[13
]}

Sorrentino, J. A. ^{[14
]}

Yang, Z. ^{[15
]}

Horton, J. K. ^{[16
]}

Tan, A. R. ^{[17
]}

机构：

[1] Texas Oncol Baylor Sammons Canc Ctr, Med Oncol, Dallas, TX USA

[2] Florida Canc Specialists, Oncol, St Petersburg, FL USA

[3] US Oncol Res, Comprehens Canc Ctr Nevada, Med Oncol, Las Vegas, NV USA

[4] Virginia Oncol Associates, Med Oncol, Norfolk, VA USA

[5] Oncol Inst Vojvodina, Med Oncol, Sremska Kamenica, Serbia

[6] St Lukes Primary Care Plaza, Med Oncol, Kansas City, MO USA

[7] H Lee Moffitt Canc Ctr & Res Inst, McKinley Outpatient Clin, Breast Oncol, Tampa, FL USA

[8] OB Opca Boln Varazdin Gen Hosp, Dept Oncol, Varazhdin, Croatia

[9] UCRO, Dept Oncol, Skopje, Macedonia

[10] Rocky Mt Canc Ctr LLP, Med Oncol, Denver, CO USA

[11] Texas Oncol PA, Med Oncol, Houston, TX USA

[12] Texas Oncol San Antonio Northeast, Med Oncol, San Antonio, TX USA

[13] Univ Nis, Clin Ctr Nis, Clin Oncol, Nish, Serbia

[14] G1 Therapuet Inc, Translat Med, Res Triangle Pk, NC USA

[15] G1 Therapuet Inc, Biostat, Res Triangle Pk, NC USA

[16] G1 Therapuet Inc, Clin Dev, Res Triangle Pk, NC USA

[17] Atrium Hlth, Levine Canc Inst, Med Oncol, Charlotte, NC USA

来源：

ANNALS OF ONCOLOGY | 2019年 / 30卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA22

引用

页码：860 / +

页数：2

共 50 条

[1] Trilaciclib improves overall survival when given with gemcitabine/carboplatin in patients with metastatic triple-negative breast cancer: Final analysis of a randomized phase 2 trial
O'Shaughnessy, Joyce
Wright, Gail S.
Thummala, Anu R.
Danso, Michael A.
Popovic, Lazar
Pluard, Timothy J.
Han, Hyo S.
Vojnovic, Zeljko
Vasev, Nikola
Ma, Ling
Richards, Donald A.
Wilks, Sharon T.
Milenkovic, Dusan
Xiao, Jie
Sorrentino, Jessica A.
Horton, Janet
Tan, Antoinette R.
CANCER RESEARCH, 2021, 81 (04)
[2] A Phase II randomized trial of pembrolizumab with carboplatin and gemcitabine for treatment of patients with metastatic triple-negative breast cancer (mTNBC)
Obeid, E.
Miller, K. D.
Sparano, J. A.
Blackwell, K.
Goldstein, L. J.
CANCER RESEARCH, 2017, 77
[3] Trilaciclib prior to gemcitabine plus carboplatin for metastatic triple-negative breast cancer: phase III PRESERVE 2
Goel, Shom
Tan, Antoinette R.
Rugo, Hope S.
Aftimos, Philippe
Andric, Zoran
Beelen, Andrew
Zhang, Jingshan
Yi, John S.
Malik, Rajesh
O'Shaughnessy, Joyce
FUTURE ONCOLOGY, 2022, 18 (33) : 3701 - 3711
[4] Trilaciclib (T), a CDK4/6 inhibitor, dosed with gemcitabine (G), carboplatin (C) in metastatic triple negative breast cancer (mTNBC) patients: Preliminary phase 2 results
O'Shaughnessy, J.
Wright, G. S.
Thummala, A. R.
Danso, M. A.
Popovic, L.
Pluard, T. J.
Cheung, E.
Han, H. S.
Daniel, B. R.
Vojnovic, Z.
Vasev, N.
Ling, M.
Richards, D. A.
Wilks, S. T.
Milenkovic, D.
Sorrentino, J. A.
Roberts, P. J.
Bomar, M.
Yang, Z.
Antal, J. M.
Malik, R. K.
Morris, S. R.
Tan, A.
CANCER RESEARCH, 2019, 79 (04)
[5] A phase II randomized trial of gemcitabine plus cisplatin(GP) vs gemcitabine plus carboplatin (GC) as the first-line treatment for patients with metastatic triple-negative breast cancer
Gong, Chengcheng
Zhao, Yannan
Wang, Leiping
Cao, Jun
Tao, Zhonghua
Li, Ting
Zhao, Mingchuan
Miao, Haitao
Jin, Juan
Hu, Xichun
Wang, Biyun
CANCER RESEARCH, 2024, 84 (09)
[6] A phase II randomized trial of gemcitabine plus cisplatin(GP) vs. gemcitabine plus carboplatin (GC) as the first-line treatment for patients with metastatic triple negative breast cancer
Gong, Chengcheng
Cao, Enying
Wang, Zhonghua
Zhang, Jian
Wang, Leiping
Cao, Jun
Zhang, Sheng
Tao, Zhonghua
Li, Ting
Zhao, Yannan
Li, Yi
Wang, Biyun
Hu, Xichun
CANCER RESEARCH, 2018, 78 (04)
[7] A phase II trial of atezolizumab (anti-PD-L1) with carboplatin in patients with metastatic triple-negative breast cancer (mTNBC).
Lander, Eric Michael
Lehmann, Brian David
Shah, Payal D.
Dees, Elizabeth Claire
Ballinger, Tarah Jean
Pohlmann, Paula Raffin
Santa-Maria, Cesar Augusto
Shyr, Yu
Mayer, Ingrid A.
Park, Ben Ho
Pietenpol, Jennifer A.
Abramson, Vandana G.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[8] A randomized phase II trial of carboplatin with or without nivolumab in metastatic triple-negative breast cancer
Garrido-Castro, Ana C.
Graham, Noah
Bi, Kevin
Park, Jihye
Fu, Jingxin
Keenan, Tanya
Richardson, Edward Thomas
Pastorello, Ricardo
Lange, Paulina
Attaya, Victoria
Wesolowski, Robert
Sinclair, Natalie
Lucas, Zarah
Lo, Steve
Tung, Nadine
Faggen, Meredith
Kaufman, Peter A.
Block, Caroline C.
Briccetti, Fred
Toke, Madhavi
Chen, Wendy
Wucherpfennig, Kai
Marx, Sascha
Agudo, Judith
Guerriero, Jennifer L.
Schnitt, Stuart
Lin, Nancy U.
Winer, Eric P.
Mittendorf, Elizabeth A.
Tayob, Nabihah
Van Allen, Eliezer
Tolaney, Sara M.
CANCER RESEARCH, 2022, 82 (04)
[9] Phase III Study of Iniparib Plus Gemcitabine and Carboplatin Versus Gemcitabine and Carboplatin in Patients With Metastatic Triple-Negative Breast Cancer
O'Shaughnessy, Joyce
Schwartzberg, Lee
Danso, Michael A.
Miller, Kathy D.
Rugo, Hope S.
Neubauer, Marcus
Robert, Nicholas
Hellerstedt, Beth
Saleh, Mansoor
Richards, Paul
Specht, Jennifer M.
Yardley, Denise A.
Carlson, Robert W.
Finn, Richard S.
Charpentier, Eric
Garcia-Ribas, Ignacio
Winer, Eric P.
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (34) : 3840 - U232
[10] A phase Ib/II study of leronlimab combined with carboplatin in patients with CCR5+metastatic triple-negative breast cancer (mTNBC)
Cristofanilli, Massimo
Chittoria, Namita
Ehsani, Sima
Rui, Hallgeir
Dolezal, Milana
Stork-Sloots, Lisette
de Snoo, Femke
Recknor, Christopher
Abramson, Vandana
CANCER RESEARCH, 2022, 82 (04)

← 1 2 3 4 5 →